Key Takeaways
- Medscheme has brought an urgent application to the Johannesburg high court to suspend or terminate requests for proposals (RFPs) issued by Bonitas Medical Fund.
- The RFPs relate to the bid for the administration of Bonitas’ scheme, currently being undertaken by Medscheme.
- A forensic investigation into Bonitas is underway, following allegations of improper procurement processes and governance failures.
- Medscheme has expressed concerns over ethical, contractual, and statutory obligations to the scheme and its members.
- The investigation is focused on a contract awarded by Bonitas to Private Health Administrators (PHA) to administer its low-income option, Boncap.
Introduction to the Dispute
Medscheme, a company that administers medical aid schemes, including for Bonitas Medical Fund, has taken urgent action to address concerns over the administration of Bonitas’ scheme. The company has brought an application to the Johannesburg high court to suspend or terminate certain requests for proposals (RFPs) issued by Bonitas in July. These RFPs relate to the bid for the administration of Bonitas’ scheme, which is currently being undertaken by Medscheme. The application is a result of concerns over ethical, contractual, and statutory obligations to the scheme and its members, which have been heightened by recent media reports alleging governance failures and procurement improprieties involving senior Bonitas executives and trustees.
Background to the Forensic Investigation
The Council for Medical Schemes (CMS) instigated a forensic investigation into Bonitas, the second-largest open medical scheme in the country, following serious allegations made against its executives and senior trustees related to improper procurement processes. The investigation is expected to take at least six months to conclude. The forensic investigation is focused on a contract awarded by Bonitas to Private Health Administrators (PHA) to administer its low-income option, Boncap. This contract removed the decades-long contract that Bonitas had with Medscheme, a subsidiary of Afrocentric Distribution Services (ADS), which is 60% held by Sanlam. Medscheme continues to administer the rest of Bonitas’ options.
Allegations of Irregularities
The allegations of irregularities and governance failures at Bonitas have been made by a whistle-blower, who has provided evidence of a concerted effort to capture the R20bn scheme from the inside. The evidence allegedly details how senior executives, trustees, and favored consultants appear to have bent procurement rules, misused confidential data, and fronted ownership structures to redirect lucrative contracts to their own circle. Bonitas has insisted that its procurement processes were properly followed and has denied the allegations of irregularities. However, the allegations have raised concerns about the governance and administration of the scheme, and the potential impact on its members.
Medscheme’s Concerns and Actions
Medscheme has expressed concerns over the potential impact of the RFPs on the scheme and its members. The company has sought to resolve these concerns amicably, requesting written assurance from Bonitas that no RFP awards would be made before the CMS investigation concludes. However, these requests were declined, prompting Medscheme to take urgent action to protect the interests of the scheme and its members. Medscheme’s application to the court is aimed at suspending or terminating the RFPs pending the conclusion of the forensic investigation. The company believes that this is necessary to ensure that the scheme is administered in a fair and transparent manner, and that the interests of its members are protected.
Implications and Potential Consequences
The implications of the dispute between Medscheme and Bonitas are significant, and the potential consequences of the forensic investigation and the court application are far-reaching. The investigation and the court application may lead to changes in the administration of the scheme, and potentially even the removal of senior executives and trustees. The dispute may also have implications for the wider medical aid industry, highlighting the need for greater transparency and accountability in the administration of medical aid schemes. The outcome of the investigation and the court application will be closely watched, as it may have significant implications for the future of Bonitas and the medical aid industry as a whole.
Conclusion
In conclusion, the dispute between Medscheme and Bonitas highlights the importance of transparency and accountability in the administration of medical aid schemes. The allegations of irregularities and governance failures at Bonitas have raised concerns about the potential impact on the scheme and its members. Medscheme’s application to the court is aimed at protecting the interests of the scheme and its members, and ensuring that the scheme is administered in a fair and transparent manner. The outcome of the investigation and the court application will be closely watched, as it may have significant implications for the future of Bonitas and the medical aid industry as a whole.